Canaccord Genuity Maintains a 'Hold' on Medifast (MED); Panned By Barron's To Begin The Diet Season

Canaccord Genuity maintains a 'Hold' on Medifast (NYSE: MED) price target of $16.00.

Canaccord analyst, Scott Van Winkle, said, "HOLD rating maintained as shares appear fully valued given expectation of no material earnings growth through at least 2012, with greater risk than upside potential to Street forecasts given the loss of momentum in its direct selling channel...Barron’s highlighted Medifast this past weekend, questioning business momentum, whether consensus forecasts for 2012 could be met, and the outlook for a 2012 share price rebound."

For an analyst ratings summary and ratings history on Medifast click here. For more ratings news on Medifast click here.

Shares of Medifast closed at $15.36 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat